Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Johnson & Johnson’s Total Sales Grow 10.7% to $23.3 Billion in Q3 - Happi
Company News, Financial News

Johnson & Johnson’s Total Sales Grow 10.7% to $23.3 Billion in Q3

The personal care giant demonstrated responsiveness to meet the needs of stakeholders in the face of evolving marketplace dynamics as a result of Covid-19.

Johnson & Johnson’s Q3 sales grew 10.7% to $23.3 billion. Earnings per share of $1.37 increased to 3.0%, and adjusted earnings per share of $2.60 increased to 18.2%.
 
“Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in pharmaceuticals, ongoing recovery in medical devices, and strong growth in consumer health,” said Alex Gorsky, chairman and chief executive officer. “In the face of evolving marketplace dynamics resulting from the effects of COVID-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of our stakeholders, while also successfully investing in a pipeline of innovation and key commercial platforms to drive our future growth.”
 
Consumer health worldwide operational sales, excluding the net impact of acquisitions and divestitures, increased 5.7% primarily driven by OTC products. Major contributors to growth included Aveeno in skin health/beauty.
 

Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Happi Newsletters